Beam Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
05. Januar 2021 06:30 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Presents Updated Data from Novel Base Editing Programs for Sickle Cell Disease at ASH 2020
05. Dezember 2020 07:00 ET
|
Beam Therapeutics
BEAM-101 Data Highlight Precision of Base Editor with No Off-Target Editing Observed; Will Support Planned IND Submission in the Second Half of 2021 In Vivo Data from Makassar Base Editing Program...
The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020
20. November 2020 16:01 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named...
Beam Therapeutics Presents First Data Highlighting Base Editing Program for Glycogen Storage Disease Type Ia at AASLD
13. November 2020 08:00 ET
|
Beam Therapeutics
Novel Base Editors for Two Most Common GSDIa Mutations Demonstrate Significantly Higher Levels of In Vivo Mutation Correction than Required to Restore Glucose Homeostasis Previously Presented Data...
Beam Therapeutics Announces Business and Pipeline Progress and Reports Third Quarter 2020 Financial Results
10. November 2020 06:30 ET
|
Beam Therapeutics
BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-ALL; First Cell Therapy Featuring Four Simultaneous Genetic Edits; Demonstrates 96-99%...
Beam Therapeutics Names First CAR-T Base Editing Development Candidate for the Treatment of T-ALL and Presents New Data at SITC 2020
09. November 2020 08:15 ET
|
Beam Therapeutics
BEAM-201, an Off the Shelf Allogeneic CD7-Targeting CAR-T, Named as Development Candidate for Treatment of T-Cell Acute Lymphoblastic Leukemia First Cell Therapy Featuring Simultaneous Edits to Four...
Beam Therapeutics to Participate in Chardan Virtual 4th Annual Genetic Medicines Conference
02. Oktober 2020 08:00 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...
Beam Therapeutics Announces Pricing of Public Offering of Common Stock
30. September 2020 20:46 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the...
Beam Therapeutics Announces Proposed Public Offering of Common Stock
28. September 2020 16:18 ET
|
Beam Therapeutics
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the...
Beam Therapeutics Announces First Development Candidates for Sickle Cell Disease and Reports Second Quarter 2020 Results
12. August 2020 06:30 ET
|
Beam Therapeutics
BEAM-101 and BEAM-102 Named as Development Candidates Targeting Distinct Approaches to Treating Sickle Cell Disease Lease Agreement Signed to Build In-house Manufacturing Facility Dedicated to...